Skip to content
Calculator
Guide

GLP-1s and birth control

Last updated: October 27, 2026 · 5 min read · By the Grey Peptides Editorial Board

Close-up of a blister pack of pink pills on a vivid yellow background for medication concept
Photo by https://kaboompics.com/ on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Tirzepatide's labels (Zepbound and Mounjaro) warn that it may make birth control pills less effective, because it slows how fast the stomach empties.
  • Both labels advise switching to a non-oral method, or adding a barrier method such as condoms, for 4 weeks after starting and for 4 weeks after every dose increase. IUDs, implants and other non-oral hormonal methods should not be affected.
  • The 'Ozempic babies' stories are anecdotal reports of unplanned pregnancies. The UK regulator says GLP-1 medicines should not be taken during pregnancy or just before trying to get pregnant, so pregnancy should be planned with a prescriber.

What the label says

The warning is written into the prescribing information. The labels for Zepbound and Mounjaro, the two brands of tirzepatide High, both say that tirzepatide may reduce the efficacy of oral hormonal contraceptives because it delays gastric emptying 1 2. They advise patients using oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting treatment and for 4 weeks after each dose escalation 1 2. Hormonal contraceptives that are not taken by mouth should not be affected 1.

Because the advice applies after every dose escalation, the 4-week window recurs each time the dose is raised 1. The labels add that the delay in gastric emptying is largest after the first dose and diminishes over time 1 2.

Why: a slower stomach

Tirzepatide slows the passage of food, and anything swallowed with it, out of the stomach. The labels report what that did to a combined oral contraceptive (ethinyl estradiol and norgestimate) taken with a single 5 mg dose of tirzepatide: peak levels of ethinyl estradiol, norgestimate and its active metabolite norelgestromin fell by 59%, 66% and 55%, overall exposure fell by 20%, 21% and 23%, and the peak came 2.5 to 4.5 hours later 1 2. A 2026 hypothesis-generating review calls this the only available pharmacokinetic study and stresses that the much smaller fall in overall exposure to the active metabolite shows a lower peak cannot be equated with reduced efficacy; whether tirzepatide changes the clinical effectiveness of oral progestogens is, in its words, untested 3.

What about semaglutide?

Semaglutide's High label is different. The current Wegovy label (version 19) reports no clinically significant differences in the pharmacokinetics of ethinyl estradiol or levonorgestrel when used with semaglutide, and carries no instruction to switch or add contraception 4. The UK regulator's guidance is broader: it says GLP-1 medicines may reduce the effectiveness of oral contraceptives in people who are overweight or obese, and suggests a non-oral method such as a coil or implant as an alternative 5. Anyone relying on the pill while starting any GLP-1 drug can ask their prescriber whether a backup method makes sense.

The 'Ozempic babies' reports

Social media and news outlets have carried many stories of unexpected pregnancies in women taking these drugs, nicknamed "Ozempic babies" 6 7. They are reports, not a measured rate. Two explanations are put forward. Weight loss itself may raise fertility: a Pharmacy Times article (trade press, by a pharmacy student, October 2024) cites a 2024 Fertility and Sterility review for weight-loss programmes averaging about 7% loss leading to more spontaneous conceptions 6. And for tirzepatide, the pill may be less reliable, as its label warns 1.

Use is rising: a 2025 review in Clinical Science notes that the number of young female users of GLP-1 drugs in the US rose 659% between 2020 and 2023 7. Ozempic is not licensed for use in pregnancy; rodent studies suggest effects on fetal growth, while emerging case reports from unplanned human pregnancies suggest no harm to the fetus 7. The UK's MHRA says GLP-1 medicines should not be taken during pregnancy or just before trying to get pregnant, and gives the gap before trying to conceive as at least 2 months for semaglutide and at least 1 month for tirzepatide 5.

What to do

If you take the pill and are starting tirzepatide, the labels give the plan: switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase 1. Methods not taken by mouth, such as an IUD, an implant, a patch or a ring, should not be affected 1. If you are planning a pregnancy, discuss timing with your prescriber before stopping contraception, including how long to stop the drug beforehand; the US semaglutide label says at least 2 months 4, and the UK guidance gives at least 1 month for tirzepatide 5.

Frequently asked questions

Does tirzepatide affect birth control?

Its labels say it may make oral contraceptives less effective, because it slows stomach emptying. They advise a non-oral method or a barrier backup for 4 weeks after starting and after each dose increase.

Does Ozempic or Wegovy affect birth control?

The current Wegovy label carries no instruction to change contraception and reports no clinically significant change in ethinyl estradiol or levonorgestrel levels. The UK regulator says GLP-1 medicines may reduce the pill's effectiveness in people who are overweight or obese. Ask your prescriber about a backup method.

What are Ozempic babies?

Unplanned pregnancies reported by women on GLP-1 drugs. They are anecdotal; the explanations put forward are weight loss raising fertility and, for tirzepatide, a less reliable pill.

Which birth control is not affected?

The tirzepatide labels say hormonal contraceptives not taken by mouth, such as implants, IUDs, patches and rings, should not be affected.

Sources

  1. Zepbound (tirzepatide) US prescribing information, sections 7.2, 8.3 and 12.3 (DailyMed set 487cd7e7-434c-4925-99fa-aa80b1cc776b, version 40, effective August 28, 2026); read October 2, re-read October 27, 2026. DailyMed
  2. Mounjaro (tirzepatide) US prescribing information, sections 7.2, 8.3 and 12.3 (DailyMed set d2d7da5d-ad07-4228-955f-cf7e355c8cc0, version 40, effective August 27, 2026); read October 27, 2026. DailyMed
  3. Viana, D. P. D. C., Invitti, A. L., Jacobsen, L., et al. (2026). Tirzepatide and oral progestogens: A hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy. Maturitas, 214, 109116. PMID: 42721915
  4. Wegovy (semaglutide) US prescribing information, sections 8.3 and 12.3 (DailyMed set ee06186f-2aa3-4990-a760-757579d8f77b, version 19, effective June 18, 2026); read October 27, 2026. DailyMed
  5. Medicines and Healthcare products Regulatory Agency (UK). GLP-1 medicines for weight loss and diabetes: what you need to know (gov.uk; first published June 5, 2025, updated February 5, 2026); read October 27, 2026. MHRA (gov.uk)
  6. Nogueira, A. C. (PharmD candidate). So-called 'Ozempic babies' raise questions about unintended effects of GLP-1 inhibitors. Pharmacy Times (trade press), October 3, 2024; citing Goldberg and Boots, Fertility and Sterility 2024. Read October 27, 2026.
  7. Dearden, L., Ozanne, S. E. (2025). Incretin receptor agonism during pregnancy: implications for mother and baby. Clinical Science, 139(23), 1597-1610. PMID: 41359794

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead